The Bill & Melinda Gates Foundation has awarded a $1.6 million grant to Surf Bio, a biopharmaceutical firm based in Palo Alto, California, that is commercializing a unique medication stabilization platform.
The cash will be used by the company to assess how well its lead technology works in improving the deliverability and thermostability of a monoclonal antibody in low- and middle-income nations.
Surf Bio, a preclinical biopharmaceutical firm led by CEO Bryan Mazlish, is using a cutting-edge biotechnology platform to create improved therapeutic solutions for autoimmune illnesses, infectious diseases, cancer, gene therapy, and other therapeutic fields.
It offers new polymer technology that makes it possible to formulate biologics in a more thermostable form and at higher concentrations than what is now possible.
“We are thrilled to receive support from the Bill & Melinda Gates Foundation to advance the use of our technology to enable greater access to biologics in low- and middle-income countries.”
CEO Bryan Mazlish
Regarding the Bill and Melinda Gates Foundation
Bill and Melinda Gates established the Bill and Melinda Gates foundation (BMGF), a private Foundation, in 2000. As of 2021, it ranked among the largest charity organizations worldwide, with an endowment exceeding $50 billion. The principal objectives of the foundation are to improve healthcare, lessen severe poverty, and increase global access to information technology and educational opportunities. Seattle, Washington, in the United States, is home to the organization’s headquarters.
Concerning Surf Bio
Using a cutting-edge biotechnology platform, Surf Bio is a preclinical biopharmaceutical firm creating improved therapeutic solutions for autoimmune diseases, infectious illnesses, cancer, gene therapy, and other therapeutic fields. The creators of Mode AGC and Bigfoot Biomedical founded Surf Bio with the goal of commercializing a ground-breaking drug stabilization technology created in the Stanford University Appel lab. Commercial applications of the technology include the ability to reduce the need for refrigeration, switch from intravenous to subcutaneous therapy, and create innovative pharmaceutical formulations for a variety of therapeutic indications.
